Table 2.
Potential epigenetic chemotherapies for oropharyngeal carcinoma
| Chemotherapeutic Agent | Status | Reference |
|---|---|---|
| DNMT inhibitors | ||
| Arsenic trioxide | Clinical Trials | [112] |
| 5- azacytidine (Vidaza, Celgene) | USFDA Approved | [47] |
| 5-aza-2′-deoxycitidine (Decitabine, Dacogen, SuperGen) | USFDA Approved | [47] |
| MG98 | Clinical trials | [122] |
| HDAC inhibitors | ||
| LAQ-824/LBH 589 (Farydak, panobinostat) | USFDA Approved | [122] |
| PXD-101(Belinostat) | Clinical trials | [122] |
| Valproic acid (Mg valproate) | Clinical trials | [122] |
| Suberoylanilide hydroxamic acid (vorinostat, SAHA) | USFDA Approved | [122] |
| FK-228 (romidepsin) | USFDA Approved | [121] |
| Phenylbutyrate | Clinical trials | [122] |
| MS-275 (entinostat) | Clinical trials | [150, 151] |
| CI-994 | Clinical trials | [90, 120] |
| MGCD-0103 (Mocetinostat) | Clinical trials | [145] |
| JNJ-26481585 (Quisinostat) | Clinical trials | [146, 147] |
| HMT inhibitors | ||
| EPZ-6438 (E7438, Epizyme) | Clinical trials | [62, 148] |
| 3-Deazaneplanocin (DZNep) | Clinical trials | [58] |
| EPZ-5676 | Clinical trials | [62] |
| EPZ-5687 | Preclinical | [58] |
| GSK-343 | Preclinical | [58] |
DZNep, 3-deazaneplanocin A; USFDA United States Food and Drug Association